LNTH — Lantheus Holdings, Inc.
Is LNTH overbought or oversold? Here is the current MarketMoodz read.
Lantheus Holdings, Inc. (LNTH) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $101.72. The rating moved from Neutral to Overbought on November 16, 2026.
- Public ratingOverbought (as of November 17, 2026)
- Last close$101.72
- Last changeMoved from Neutral to Overbought on November 16, 2026
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
See all overbought Healthcare stocks →
AI analysis
Lantheus Holdings, Inc. (LNTH) benefits from a differentiated radiopharmaceutical portfolio and improving commercial adoption of advanced PET agents, producing procedure-linked recurring revenue and attractive margin expansion potential. Its specialized manufacturing and distribution capabilities create practical barriers to entry and support near-term growth from label expansions and rollouts. Macro and sector flows into defensive healthcare exposures provide supportive investor interest. Key vulnerabilities include reimbursement/headwinds from Medicare or MA plan changes, regulatory risk for radiopharmaceuticals, competitive pressure from alternative imaging solutions, and operational/production complexities tied to short-lived drugs. The outlook is dependent on steady commercial execution, successful scaling of manufacturing, and favorable reimbursement trends; adverse regulatory or payment developments would materially impair revenue trajectories.
Key factors
- Leading diagnostic radiopharmaceutical portfolio with commercialized PET agents supporting recurring, procedure-linked revenue
- Solid commercial traction and increasing adoption of advanced imaging agents that drive higher-margin sales and visibility
- Manufacturing and supply-chain capabilities for radiopharmaceuticals provide a competitive barrier to entry
- Sector flows into defensive, large-cap healthcare increase investor interest in healthcare exposure and specialty imaging names
- Readthroughs from broader specialty care and distributor shifts support sustained prescription and distribution volumes
- Multiple near-term revenue catalysts from label expansions, commercial rollouts and potential new product launches
Risks
- Reimbursement pressure and changes in Medicare/Medicare Advantage policies could materially reduce procedure volumes or pricing
- Regulatory setbacks, delayed approvals or adverse safety signals for radiopharmaceuticals could sharply impact revenue and sentiment
- Competition from other imaging modalities, alternative PET agents or large pharma entrants could constrain market share
- Manufacturing, scale-up or supply disruptions for short-lived radiopharmaceuticals could lead to lost procedures and customer churn
- Concentration risk around a small number of flagship products or large customers could amplify downside if adoption slows
- Political/regulatory moves (e.g., changes to payment models or PBM/insurer dynamics) could increase uncertainty for utilization
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for LNTH — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.